Lessons From the Avandia Controversy
- 1 December 2007
- journal article
- editorial
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (12) , 3141-3144
- https://doi.org/10.2337/dc07-1908
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- The Avandia DebateDiabetes Care, 2007
- A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placeboBMC Endocrine Disorders, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Rosiglitazone and Cardiovascular RiskNew England Journal of Medicine, 2007
- Standards of Medical Care in Diabetes—2007Diabetes Care, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- PROactive: A Sad Tale of Inappropriate Analysis and Unjustified InterpretationClinical Diabetes, 2006
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993